George Y Wang
Examiner (ID: 4033)
Most Active Art Unit | 2871 |
Art Unit(s) | 2882, 2871 |
Total Applications | 215 |
Issued Applications | 148 |
Pending Applications | 11 |
Abandoned Applications | 56 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 14342247
[patent_doc_number] => 20190153096
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-23
[patent_title] => CD3/CD33 BISPECIFIC BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/140576
[patent_app_country] => US
[patent_app_date] => 2018-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16140576
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/140576 | CD3/CD33 BISPECIFIC BINDING MOLECULES | Sep 24, 2018 | Abandoned |
Array
(
[id] => 15422611
[patent_doc_number] => 10544219
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-28
[patent_title] => TIGIT-binding agents and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/138418
[patent_app_country] => US
[patent_app_date] => 2018-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 56
[patent_no_of_words] => 67049
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16138418
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/138418 | TIGIT-binding agents and uses thereof | Sep 20, 2018 | Issued |
Array
(
[id] => 16328418
[patent_doc_number] => 20200299384
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => NOVEL ANTI-CD3EPSILON ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/649149
[patent_app_country] => US
[patent_app_date] => 2018-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22555
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649149
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/649149 | Anti-CD3epsilon antibodies | Sep 19, 2018 | Issued |
Array
(
[id] => 16252265
[patent_doc_number] => 20200261639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNA
[patent_app_type] => utility
[patent_app_number] => 16/648045
[patent_app_country] => US
[patent_app_date] => 2018-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648045
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/648045 | Method and device for purification of blood from circulating cell free DNA | Sep 16, 2018 | Issued |
Array
(
[id] => 13957935
[patent_doc_number] => 20190055311
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-21
[patent_title] => Agents for Treatment of Claudin Expressing Cancer Diseases
[patent_app_type] => utility
[patent_app_number] => 16/117197
[patent_app_country] => US
[patent_app_date] => 2018-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62108
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16117197
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/117197 | Agents for treatment of claudin expressing cancer diseases | Aug 29, 2018 | Issued |
Array
(
[id] => 17633916
[patent_doc_number] => 11344621
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-31
[patent_title] => Interleukin-13 binding proteins
[patent_app_type] => utility
[patent_app_number] => 16/113027
[patent_app_country] => US
[patent_app_date] => 2018-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44597
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16113027
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/113027 | Interleukin-13 binding proteins | Aug 26, 2018 | Issued |
Array
(
[id] => 13733209
[patent_doc_number] => 20180371072
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-27
[patent_title] => COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/112304
[patent_app_country] => US
[patent_app_date] => 2018-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16112304
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/112304 | COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS | Aug 23, 2018 | Abandoned |
Array
(
[id] => 14158783
[patent_doc_number] => 20190106494
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-11
[patent_title] => PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
[patent_app_type] => utility
[patent_app_number] => 16/111158
[patent_app_country] => US
[patent_app_date] => 2018-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17652
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111158
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/111158 | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis | Aug 22, 2018 | Abandoned |
Array
(
[id] => 14019027
[patent_doc_number] => 20190071507
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-07
[patent_title] => ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/055947
[patent_app_country] => US
[patent_app_date] => 2018-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24324
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16055947
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/055947 | Antibodies against human CSF-1R and uses thereof | Aug 5, 2018 | Issued |
Array
(
[id] => 17177371
[patent_doc_number] => 11154600
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-26
[patent_title] => Use of anti-CD47 agents to enhance immunization
[patent_app_type] => utility
[patent_app_number] => 16/048862
[patent_app_country] => US
[patent_app_date] => 2018-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 30
[patent_no_of_words] => 15073
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16048862
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/048862 | Use of anti-CD47 agents to enhance immunization | Jul 29, 2018 | Issued |
Array
(
[id] => 15816573
[patent_doc_number] => 10633452
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-04-28
[patent_title] => Anti-cancer antibodies with reduced complement fixation
[patent_app_type] => utility
[patent_app_number] => 16/026846
[patent_app_country] => US
[patent_app_date] => 2018-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 12
[patent_no_of_words] => 5235
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026846
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/026846 | Anti-cancer antibodies with reduced complement fixation | Jul 2, 2018 | Issued |
Array
(
[id] => 14375279
[patent_doc_number] => 20190161552
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-30
[patent_title] => ANTI-BCMA ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/026242
[patent_app_country] => US
[patent_app_date] => 2018-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14891
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026242
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/026242 | Anti-BCMA antibodies | Jul 2, 2018 | Issued |
Array
(
[id] => 13493131
[patent_doc_number] => 20180298108
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-18
[patent_title] => THERAPEUTIC ANTIBODIES AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 16/017974
[patent_app_country] => US
[patent_app_date] => 2018-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59353
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16017974
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/017974 | Therapeutic antibodies and their uses | Jun 24, 2018 | Issued |
Array
(
[id] => 13870887
[patent_doc_number] => 20190031784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-31
[patent_title] => T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/016209
[patent_app_country] => US
[patent_app_date] => 2018-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75009
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16016209
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/016209 | T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES | Jun 21, 2018 | Abandoned |
Array
(
[id] => 16072445
[patent_doc_number] => 20200190209
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => CD38 MODULATING ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/620584
[patent_app_country] => US
[patent_app_date] => 2018-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50827
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -76
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620584
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/620584 | CD38 modulating antibody | Jun 7, 2018 | Issued |
Array
(
[id] => 17815441
[patent_doc_number] => 11421040
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => Antibodies specific for FLT3 and their uses
[patent_app_type] => utility
[patent_app_number] => 15/993874
[patent_app_country] => US
[patent_app_date] => 2018-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 11
[patent_no_of_words] => 31219
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 974
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15993874
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/993874 | Antibodies specific for FLT3 and their uses | May 30, 2018 | Issued |
Array
(
[id] => 13574965
[patent_doc_number] => 20180339031
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-29
[patent_title] => ANTI-CD47 X ANTI-MESOTHELIN ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/991774
[patent_app_country] => US
[patent_app_date] => 2018-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991774
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/991774 | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof | May 28, 2018 | Issued |
Array
(
[id] => 13397727
[patent_doc_number] => 20180250406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-06
[patent_title] => RS7 Antibodies
[patent_app_type] => utility
[patent_app_number] => 15/980057
[patent_app_country] => US
[patent_app_date] => 2018-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23168
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980057
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/980057 | RS7 antibodies | May 14, 2018 | Issued |
Array
(
[id] => 14309649
[patent_doc_number] => 20190144528
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => Immunoglobulins Directed to Bacterial, Viral and ENDOGENOUS Polypetides
[patent_app_type] => utility
[patent_app_number] => 15/978801
[patent_app_country] => US
[patent_app_date] => 2018-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15978801
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/978801 | Immunoglobulins directed to bacterial, viral and endogenous polypetides | May 13, 2018 | Issued |
Array
(
[id] => 15993489
[patent_doc_number] => 20200172615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => NOVEL METHOD FOR PRODUCING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/611856
[patent_app_country] => US
[patent_app_date] => 2018-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611856
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/611856 | NOVEL METHOD FOR PRODUCING ANTIBODIES | May 7, 2018 | Abandoned |